Drug Profile
NLS 2
Alternative Names: NLS2Latest Information Update: 07 Jan 2022
Price :
$50
*
At a glance
- Originator NeuroLifeSciences
- Developer NLS Pharmaceutics Ltd
- Class Antianaemics; Heavy metals
- Mechanism of Action Iron replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder; Restless legs syndrome
Most Recent Events
- 25 Sep 2020 No development reported - Phase-III for Attention-deficit hyperactivity disorder in France (unspecified route) (NLS Pharmaceutics pipeline, September 2020)
- 25 Sep 2020 No development reported - Phase-III for Restless legs syndrome in France (unspecified route) (NLS Pharmaceutics pipeline, September 2020)
- 19 Mar 2019 NLS Pharma Ltd, NLS-1 Pharma Ltd and NLS-0 Pharma merged to form NLS Pharmaceutics Ltd